Skip to main content

HHLR Advisors (Hillhouse)

Superinvestor

HHLR Advisors, Ltd.

SEC CIK
0001762304
Manager
Zhang Lei
Style
Growth
Latest filing
Aug 14, 2026

AKRO holding history

Akero Therapeutics, Inc. in every 13F filed by HHLR Advisors (Hillhouse), including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

AKRO overviewAll 13F holders of AKROFull Q2 2026 holdings

Shares (Q4 2023)
0
Sold out in Q4 2023
Value
$0
% of portfolio
0.0%
Quarters held
11
Since Q1 2021
Holdings of AKRO by HHLR Advisors (Hillhouse), by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q4 20230$00.0%−273,002−100.0%Sold outHolders
Q3 2023273,002$13.8M0.3%00.0%UnchangedHolders
Q2 2023273,002$12.7M0.3%−22,500−7.6%ReducedHolders
Q1 2023295,502$11.3M0.2%−20,000−6.3%ReducedHolders
Q4 2022315,502$17.3M0.4%−364,498−53.6%ReducedHolders
Q3 2022680,000$23.2M0.6%−679,052−50.0%ReducedHolders
Q2 20221,359,052$12.8M0.3%−1000.0%ReducedHolders
Q1 20221,359,152$19.3M0.4%00.0%UnchangedHolders
Q4 20211,359,152$28.7M0.4%−181,313−11.8%ReducedHolders
Q3 20211,540,465$34.4M0.5%−116,208−7.0%ReducedHolders
Q2 20211,656,673$41.1M0.4%00.0%UnchangedHolders
Q1 20211,656,673$48.1M0.5%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.